CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In our hands 3 μM nilotinib on average induces only about 5–10% apoptosis above background level in NDC (DMSO) in CD34+ CML-CP cells after 72 h in vitro (data not shown).